Results 81 to 90 of about 3,132 (216)

Safety profile of faricimab: a multi-source pharmacovigilance analysis using FAERS and JADER

BMC Pharmacology and Toxicology
Faricimab is a bispecific antibody targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), offering a novel therapeutic approach for ocular diseases. However, its long-term safety profile remains under evaluation.
Chuanya Liu, Shangze Li, Ziyi Wang, Zhifu Li, Z. Fang, Yuan Zhang, Yu Gao   +6 more
semanticscholar   +1 more source

Real-World Data on Morphological and Functional Responses After Switching to Faricimab in Recalcitrant, Chronic Diabetic Macular Edema

Ophthalmology and Therapy
Introduction This study aimed to assess the morphological and functional effects of faricimab in patients with chronic diabetic macular edema (DME) who had an insufficient response to previous treatments.
Viktoria Deiters, Anna Lorger, Franziska Eckardt, Jakob Siedlecki, Benedikt Schworm, Siegfried G. Priglinger, Tina R. Herold   +6 more
doaj   +1 more source

Real-World Outcomes of Faricimab Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema [PDF]

Nicole QX Quah, Khawaja Muhammad Ammar Ali Javed, Lamees Arbi, Daren Hanumunthadu Department of Ophthalmology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UKCorrespondence: Daren Hanumunthadu, Department of Ophthalmology, Royal ...
Hanumunthadu D, Quah NQX, Javed KMAA, Arbi L   +3 more
core  

Switching to Faricimab or High‐Dose Aflibercept for Neovascular AMD in High‐Demand Patients: Impact on Injection Interval in a Real‐World Cohort

Clinical &Experimental Ophthalmology, Volume 54, Issue 5, Page 724-726, July 2026.
Zachary George Angus, Yin‐Zhi Lee, Sukhpal Singh Sandhu, Robyn Troutbeck, Jonathan Yeoh, Daniel Chiu, Manishka Jayasundera, Jaesser Tan, Sanjeewa Wickremasinghe   +8 more
wiley   +1 more source

Quantitative analysis of vitreous changes in intraocular inflammation following faricimab treatment in a real world setting

International Journal of Retina and Vitreous
Background To analyze the incidence, and clinical characteristics of intraocular inflammation (IOI) associated with faricimab in a tertiary center in Austria.
Clemens Thürridl, Konrad Dörfler, Jan Rothbächer, Markus Eidherr, Haidar Khalil, Josef Huemer, Matthias Bolz   +6 more
doaj   +1 more source

Comparative efficacy and safety of Faricimab with other intravitreal anti-vascular endothelial growth factor in the treatment of Neovascular age related macular degeneration- A Systematic review and meta-analysis

Asian Journal of Medical Sciences
Age-related macular degeneration (AMD) is the leading cause of visual impairment in patients age 50 and older, with an estimated 200 million people affected worldwide.
Renuga Devi Kaliaperumal , Nandhini P, Reena Mohan , Nallamuthu P , Jenifer Florence Mary J   +4 more
doaj   +1 more source

Outcomes After Switching to Faricimab for Refractive Macular Edema in Treatment-Experienced Eyes with Neovascular Age-Related Macular Degeneration [PDF]

Yaqoob Qaseem,1 Kirk Kohwa Hou,1,2 Moritz S Pettenkofer1 1Retina Division, Stein Eye Institute, University of California Los Angeles, Los Angeles, CA, USA; 2Doheny Eye Institute, Los Angeles, CA, USACorrespondence: Moritz S Pettenkofer, Retina Division ...
Pettenkofer MS, Qaseem Y, Hou KK
core  

Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology
To report short-term outcomes of treatment switch to faricimab in real-world patients with aflibercept-resistant neovascular age-related macular degeneration (AMD).
Miklos Schneider, Jakob Bjerager, Delila Hodzic-Hadzibegovic, O. Klefter, Y. Subhi, J. Hajari   +5 more
semanticscholar   +1 more source

BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion

, 2023
Purpose: Dual inhibition of angiopoietin-2 and VEGF-A with faricimab (Vabysmo) offers excellent visual acuity gains with strong durability in patients with diabetic macular edema (ME) and neovascular age-related macular degeneration.
Carl J. Danzig, MD, Ying Liu, PhD, Karen Basu, PhD, Anat Loewenstein, MD, Aachal Kotecha, PhD, Jeffrey R. Willis, MD, PhD, Robyn Guymer, MD, PhD, Charles C. Wykoff, MD, PhD, András Seres, MD, Pablo Arrisi, PhD, Francis Abreu, PhD, Zdenka Haskova, MD, PhD, Liliana P. Paris, MD, PhD, Lars-Olof Hattenbach, MD, PhD, Jeffrey S. Heier, MD   +14 more
core   +1 more source

Faricimab reverts VEGF-A165-induced impairment of the barrier formed by retinal endothelial cells

VEGF-A165-induced persistent dysfunction of the barrier formed by immortalized bovine retinal endothelial cells (iBREC) is only transiently reverted by inhibition of VEGF-A-driven signaling.
Fuezy, Isabell, Deissler, Heidrun L., Lytvynchuk, Lyubomyr, Jung, Dominik M.   +3 more
core   +2 more sources